Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
Premium Increases for Seniors
[By Staff Writers]
Medicare Past D, the prescription drug benefit set forth under the MMA is variable by the plan vendor, with premium rates set on an annual basis.
Cost sharing is subsidized for qualified Medicaid/Medicare crossovers and specified low-income beneficiaries. The MMA allows for the deductible and variable coinsurance coverage levels to increase on an annual basis in subsequent years.
The standard benefit and cost sharing for 2008 is:
· Annual Deductible of $275;
· 25% Coinsurance for covered drugs costs between $276 and $2,510;
· 100% Coinsurance (no plan coverage) of the cost of covered drugs between $2,511 and $5,726.25;
· The Maximum beneficiary annual out of pocket, which determines the upper limit of no plan coverage as stated above is $4,050; and
· 5% coinsurance of the cost of covered drugs above $5,726.25 (or a co-payment of $2.25 for covered generics and $5.60 for covered brand-name drugs-whichever is greater).
Assessment
Now, in accordance with the Medicare Modernization Act, single beneficiaries and married couples with annual incomes exceeding a specified amount now pay a higher percentage of the cost of Medicare Part B coverage, through the Part B premium.
These higher-income beneficiaries will pay a monthly premium equal to 35, 50, 65, or 80% of the total cost, depending on their income level, by the end of the 3-year transition period that started in 2007.
Conclusion
Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.
Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos
Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com
OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:
DICTIONARIES: http://www.springerpub.com/Search/marcinko
PHYSICIANS: www.MedicalBusinessAdvisors.com
PRACTICES: www.BusinessofMedicalPractice.com
HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
CLINICS: http://www.crcpress.com/product/isbn/9781439879900
BLOG: www.MedicalExecutivePost.com
FINANCE: Financial Planning for Physicians and Advisors
INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors
Share this:
Filed under: Drugs and Pharma | Tagged: Big Pharma and Drugs | 5 Comments »
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 